NHS to trial anti-cholesterol jab in pioneering collaboration with Novartis

Latest

NHS to trial anti-cholesterol jab in pioneering collaboration with Novartis

In Latest

The Government is planning an innovative collaboration with the pharmaceutical company Novartis aimed at tackling cardiovascular disease, in which the NHS will conduct trials of an as yet unlicensed injectable alternative to statins.

Inclisiran is currently the first and only cholesterol-lowering therapy in the siRNA (small-interfering RNA) class. It is in Phase III clinical development and has not been approved by any regulatory authority. It is administered as an injection twice a year.

As a siRNA, inclisiran harnesses the body’s natural process of RNA interference to specifically prevent production of the PCSK9 protein in the liver. This enhances the liver’s ability to remove LDL-C from the bloodstream, thereby lowering LDL-C levels and preventing the build-up of plaque in the arteries.

Early results from clinical trials suggest that if inclisiran is given to 300,000 patients annually in the UK, it could help prevent 55,000 heart attacks and strokes, and has the potential of saving 30,000 lives in the next 10 years.

The results of the ORION-9 study, announced at the American Heart Association meeting in November 2019, showed inclisiran achieved a lowering of 50 per cent in LDL-C with time-adjusted reductions of 45 per cent sustained over 18 months in patients with heterozygous familial hypercholesterolemia. It also demonstrated an excellent safety profile, with no treatment-related liver or renal abnormalities

Large-scale trial

Heart disease is the second biggest cause of death in the UK, with over 3 million people suffering from atherosclerotic cardiovascular disease and 2.5 million currently relying on statins to lower their cholesterol.

The DHSC is presenting the collaboration with Novartis as an example of how the UK can facilitate large-scale prevention trials by addressing implementation and manufacturing issues early on through research funded by government.

The agreement could make a significant contribution towards meeting the NHS Long Term Plan commitment to preventing 150,000 cardiovascular deaths over 10 years.

Inclisiran will be studied as part of a large-scale clinical trial expected to start later this year. The five year trial will look at the use of the drug in primary prevention patients and will be the first in the world to treat such a patient population. The trial is being supported by the National Institute for Health Research (NIHR), which is funded by the DHSC.

EMA approval

Inclisiran was developed by The Medicines Company, which was bought by Novartis in November 2019. The memorandums of understanding that form the basis of the collaboration were agreed prior to the acquisition.

The drug is expected to file for regulatory approval with the European Medicines Agency (EMA) in the first quarter of 2020 as a preventative add-on treatment to statins for patients who have already been diagnosed with cardiovascular disease.

Upon approval and NICE assessment, the intention is that NHS England will agree a population-level commercial arrangement with Novartis to make inclisiran available to patients as soon as 2021.

Sir John Bell, professor of medicine at the University of Oxford’s medical science division, said: “The discovery and development of Inclisiran marks an important change in the approach to pharmaceutical interventions for public health. This program has introduced the use of health care system data from the NHS to dramatically reduce costs by rapidly identifying patient populations through health records.

Professor of medicine and epidemiology at the University of Oxford, Martin Landray, said: “The trial will provide both a very reliable test of the efficacy and safety of inclisiran to support a population-health approach to the management of cholesterol, and act as an exemplar for future trials of other treatments in the UK.”

Record my learning outcomes

Latest

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
Latest

Locate a Locum Learning launched

Locate Learning launches today, increasing members access to extensive learning library.

1 Min Article

bookmark_icon_off
Latest

MHRA issues thermometer warning

MHRA issues thermometer warning after increase in the number of unreliable products available in the UK. 

1 Min Article

bookmark_icon_off
Latest

Nearly 90 per cent of adults would have tested positive for Covid-19 antibodies in June, says ONS

ONS estimates vast majority would have had antibodies in mid-June.

1 Min Article

bookmark_icon_off
Latest

New NHS clinics to provide pelvic floor support for women

Pregnant women and new mums are to receive support from new NHS clinics.

1 Min Article

bookmark_icon_off
Latest

NICE recommends mental health support for people with acne

Mental health support is key in managing acne vulgaris, says clinical watchdog.

1 Min Article

bookmark_icon_off
Latest

RPS calls for action on women's health inequalities

Action is needed to reduce the inequalities faced by women when accessing health services, the Royal Pharmaceutical Society has said. 

1 Min Article

bookmark_icon_off
Latest

Reports of potential bidding war over LloydsPharmacy

LloydsPharmacy could be the target of a three-way bidding war fought among financial investors over the next few weeks, it has been reported.

1 Min Article

bookmark_icon_off
Latest

Dukes to leave PSNC in September

PSNC chief executive Simon Dukes will leave his post at the end of September after just over three and-a-half years in the role.

1 Min Article

bookmark_icon_off
Latest

NHSE: Pharmacy must speak 'as one' to gain power

Community pharmacies need to speak 'as one' to gain greater influence within primary care, a senior NHS England official has said. 

1 Min Article

bookmark_icon_off
Latest

E-cig loophole puts minors at risk, Government told

A charity criticises the government for failing to close a loophole allowing companies to hand out free e-cigarettes to under-18s. 

1 Min Article

bookmark_icon_off
Latest

Lloyds pulls nasal spray over 'bold' Covid claims

LloydsPharmacy has "paused" sales of a £15 nasal spray that claims to neutralise the coronavirus before it can make people ill.

1 Min Article

bookmark_icon_off
Latest

DH sets ambitious targets for winter flu programme

The Department of Health and Social Care announces that it aims to vaccinate 85 per cent of people aged 65 and over against influenza.

1 Min Article

bookmark_icon_off
Latest

Wright review group to hold focus groups to form proposals

The Wright review steering group will hold a series of online focus groups and workshops this month and in August.

1 Min Article

bookmark_icon_off
Latest

Two Solihull pharmacists jailed for illegal supply of POMs

Dean Dookhan and Narvinder Nandra pleaded guilty to two charges concerning the illegal supply of 21,000 Zolpidem pills.

1 Min Article

bookmark_icon_off
Latest

Pharmacist to run London marathon for charity

Pharmacist Mohammed Hussain will run the London marathon to raise money for Pharmacist Support.

1 Min Article

bookmark_icon_off
Latest

Boots opens flu jab bookings as demand soars

Boots says it has opened bookings for its winter flu jab service amid reports of soaring demand. 

1 Min Article

bookmark_icon_off
Latest

Running app downloaded over five million times this month

The Couch to 5K app contains advice and information from a celebrity coach to help users record their progress. 

1 Min Article

bookmark_icon_off
Latest

Drug companies fined £260m for "excessive and unfair" price hikes to hydrocortisone tablets over a 10 year period.

1 Min Article

bookmark_icon_off
Latest

IBS sufferers worried about return to workplace

People with irritable bowel syndrome are anxious about lockdown easing and the prospect of going back to the workplace contributing to their symptoms.

1 Min Article

bookmark_icon_off
Latest

GPhC too soft on corporate multiples claims PDA

The GPhC is disproportionately tough on individual registrants compared to pharmacy owners and premises, the PDA has claimed. 

1 Min Article

Recommended Learning

Sponsored education

Supporting parents of babies with feeding issues

Common feeding feeding issues, including coloc, reflux and regurgitation, and some of the ways they can be managed

10 Min Module

bookmark icon off
Sponsored education

OTC Omeprazole tablets 20mg: an opportunity for pharmacy

This module highlights a new opportunity to treat heartburn and reflux in the pharmacy with Omeprazole 20mg, which is newly available for customers to purchase OTC.

10 Min Module

Sponsored education

Covid-19 and mental health

Viatris has created this short video based on a publication reviewing global research into the potential impact of the Covid-19 pandemic on mental health. It identifies six areas where psychiatrists can play a role in supporting people's mental health through these difficult times.

4 Min Module

Sponsored education

Advising on very dry and eczema-prone skin

This video will guide you through a consultation with Michelle, a customer with very dry skin, and help you recommend suitable products to help

2 Min Module

bookmark icon off
Bayer Business Programme

Make it Count: Manager version

This training offers new insights into the customers of today and explores how you and your team can adapt your sales approach to engage with customers in order to grow your business.

15 Min Module

bookmark icon off
Sponsored education

Managing dry eye and blepharitis

Discover the link between dry eye and blepharitis and learn how to help customers effectively manage these conditions.

10 Min Module